Research Papers:

Genetic variants of genes in the Notch signaling pathway predict overall survival of non-small cell lung cancer patients in the PLCO study

Yinghui Xu, Yanru Wang, Hongliang Liu, Xiaozheng Kang, Wei Li and Qingyi Wei _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:61716-61727. https://doi.org/10.18632/oncotarget.11436

Metrics: PDF 1575 views  |   HTML 2295 views  |   ?  


Yinghui Xu1,2,3, Yanru Wang2,3, Hongliang Liu2,3, Xiaozheng Kang2,4, Wei Li1, Qingyi Wei2,3

1Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China

2Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA

3Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA

4Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing 100142, China

Correspondence to:

Wei Li, email: [email protected]

Qingyi Wei, email: [email protected]

Keywords: lung cancer, GWAS, Notch pathway, overall survival (OS), single nucleotide polymorphism (SNP)

Received: May 09, 2016     Accepted: August 11, 2016     Published: August 20, 2016


The Notch signaling pathway has been shown to have biological significance and therapeutic application in non-small cell lung cancer (NSCLC). We hypothesize that genetic variants of genes in the Notch signaling pathway are associated with overall survival (OS) of NSCLC patients. To test this hypothesis, we performed multivariate Cox proportional hazards regression analysis to evaluate associations of 19,571 single nucleotide polymorphisms (SNPs) in 132 Notch pathway genes with OS of 1,185 NSCLC patients available from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. We found that five potentially functional tagSNPs in four genes (i.e., ADAM12 rs10794069 A > G, DTX1 rs1732793 G > A, TLE1 rs199731120 C > CA, TLE1 rs35970494 T > TC and E2F3 rs3806116 G > T) were associated with a poor OS, with a variant-allele attributed hazards ratio (HR) of 1.27 [95% confidence interval (95% CI) = 1.13–1.42, P = 3.62E-05], 1.30 (1.14–1.49, 8.16E-05), 1.40 (1.16–1.68, 3.47E-04), 1.27 (1.11–1.44, 3.38E-04), and 1.21 (1.09–1.33, 2.56E-04), respectively. Combined analysis of these five risk genotypes revealed that the genetic score 0–5 was associated with the adjusted HR in a dose-response manner (Ptrend = 3.44E-13); individuals with 2–5 risk genotypes had an adjusted HR of 1.56 (1.34–1.82, 1.46E-08), compared with those with 0–1 risk genotypes. Larger studies are needed to validate our findings.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11436